<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02384083</url>
  </required_header>
  <id_info>
    <org_study_id>POMDEFIL</org_study_id>
    <nct_id>NCT02384083</nct_id>
  </id_info>
  <brief_title>Filanesib (ARRY-520) in Combination With Pomalidomide and Dexamethasone for Relapsed/Refractory (R/R) Multiple Myeloma (MM) Patients</brief_title>
  <official_title>Phase I/II, Multicenter, Open Label, Clinical Trial of Filanesib (ARRY-520) in Combination With Pomalidomide and Dexamethasone for Relapsed/Refractory (R/R) Multiple Myeloma (MM) Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PETHEMA Foundation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Array BioPharma</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Celgene Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>PETHEMA Foundation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase I/II, Multicenter, Open Label, Clinical Trial to evaluate safety and efficacy and
      determine the Maximum Tolerated Dose (MTD) of Filanesib in combination with pomalidomide and
      dexamethasone in relapsed/refractory (R/R) Multiple Myeloma (MM) patients
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      National, multicenter, open label single-arm, non-comparative study, that will evaluate the
      MTD and the efficacy of the Kinesin Spindle Protein (KSP) inhibitor Filanesib (ARRY-520) in
      combination with pomalidomide + dexamethasone in relapsed or refractory MM patients.

      For this purpose, relapsed or refractory MM patients after at least two prior lines of
      therapy including bortezomib and lenalidomide, who are refractory or intolerant to
      lenalidomide and refractory to the last line of therapy will be treated with 28-day cycles of
      Filanesib administered iv as a 1-hour (± 10-minute) infusion at escalating doses on days 1,
      2, 15 &amp; 16, + pomalidomide administered po at escalating doses during 21 days with 7 days
      rest period + dexamethasone at a fixed dose of 40 mg po days 1, 8, 15 &amp; 22. G-CSF prophylaxis
      is mandatory in all patients after Filanesib, starting from Day 3 and Day 17 (for a total of
      7 days each). Treatment will be continued until progression or unacceptable toxicity.

      Initially, a Phase I will be conducted using a modified 3+3 dose-escalating algorithm. The
      first three patients will be enrolled in the first dose level (see Figure 1 for dose
      escalation levels). If no DLT occurs among them, the next cohort of three patients will
      continue at the next higher dose level. If a DLT occurs among the first three evaluable
      patients during the first cycle, three more patients will be enrolled at the same dose level.

      If no more than one DLT is observed among the six evaluable patients in this expanded dose
      group during cycle 1, enrollment will continue at the next higher dose level following the
      same scheme.

      If more than one DLT occurs among the three or six evaluable patients included in the 1st
      cohort, an alternative dose escalation will be started, with a reduction of the dose of
      pomalidomide (see Figure 1). Patients will be then treated following again the same 3+3
      algorithm. If more than one DLT out of three or six patients occur at the first dose level of
      the alternative escalation, the study will be stopped.

      MTD will be considered as the dose level in which ≤1 DLT are observed among 6 evaluable
      patients, therefore, at least six patients must be treated at a given dose before this dose
      is considered the MTD.

      Once the MTD is determined in Phase I, additional patients will be treated at this dose in
      the Phase II portion of the trial in order to define the activity and further define the
      toxicity of the combination at the MTD.

      Patient participation in the study will comprise several periods:

      The pre-treatment period includes the screening visit. After providing the written Informed
      Consent form to participate in the study, patients will be evaluated for eligibility during a
      screening period of up to 21 days (Days -21 to -1).

      During the treatment period, all patients will receive Filanesib in combination with
      pomalidomide and dexamethasone in 28-days-cycles until progression or unacceptable toxicity.

      Patients receiving the combination will be evaluated for efficacy and toxicity after the
      completion of each cycle.

      No intra-patient escalation will be performed, that is, patients included at a given dose
      level during the Phase I will remain at this dose level during all treatment unless a dose
      reduction is required for toxicity.

      All patients that discontinue treatment for any other cause different to disease progression
      will be evaluated in the follow-up period every two months for 1 additional year, for disease
      status, survival and safety (including second primary malignancies). All patients that have
      progressed at the end of treatment will be followed for survival and safety only (including
      second primary malignancy), being phone contact acceptable.

      Patients will be considered to be on-study from the signature of the Informed Consent to the
      end of the follow-up period. Patients will be considered to be on-treatment for the duration
      of their treatment and in the first 30 days following treatment discontinuation. Treatment
      discontinuation is defined as the day of the last study drug dose administration.

      Patients will receive the study combination while it is considered to be in their best
      interest. Specifically, treatment will continue until one or more of the following events
      occur:

        -  Disease progression.

        -  Unacceptable toxicity.

        -  Patient refusal.

        -  Intercurrent serious illness.

        -  Protocol deviation with an effect on the risk/benefit ratio of the clinical trial.

        -  Treatment delay &gt; 4 weeks (except in case of clear clinical benefit, with the sponsors'
           approval).

        -  Study closure.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">September 2015</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Actual">February 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maxim Tolerability Dose measured by common toxicity criteria v4.0</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Eficcacy measured by the rate of responses</measure>
    <time_frame>6 months</time_frame>
    <description>Efficacy of the Kinesin Spindle Protein (KSP) inhibitor Filanesib (ARRY-520) in combination with pomalidomide + dexamethasone in relapsed or refractory MM patients.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">47</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>Filanesib, pomalidomide and dexamethasone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>28-day cycles of Filanesib administered iv as a 1-hour (± 10-minute) infusion at escalating doses on days 1, 2, 15 &amp; 16, + pomalidomide administered p.o. at escalating doses during 21 days with 7 days rest period + dexamethasone at a fixed dose of 40 mg po days 1, 8, 15 &amp; 22</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Filanesib, pomalidomide and dexamethasone</intervention_name>
    <description>Patients will be treated with 28-day cycles of Filanesib administered iv as a 1-hour (± 10-minute) infusion at escalating doses on days 1, 2, 15 &amp; 16, + pomalidomide administered p.o. at escalating doses during 21 days with 7 days rest period + dexamethasone at a fixed dose of 40 mg po days 1, 8, 15 &amp; 22. G-CSF prophylaxis is mandatory in all patients after Filanesib, starting from Day 3 and Day 17 (for a total of 7 days each). Treatment will be continued until progression or unacceptable toxicity.</description>
    <arm_group_label>Filanesib, pomalidomide and dexamethasone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥18 years.

          -  Performance status (ECOG) ≤ 2.

          -  Patient is, in the Investigator's opinion, willing and able to comply with the
             protocol requirements.

          -  Patient has given voluntary written Informed Consent before performance of any
             study-related procedure not part of normal medical care, with the understanding that
             consent may be withdrawn by the patient at any time without prejudice to their future
             medical care.

          -  Patients previously diagnosed with MM according to the IMWG Criteria (Blood 2011) that
             after previous treatment with at least 2 regimens require therapy due to a
             relapse/progression of the disease.

          -  Regarding the disease history, patient must:

               -  Have received 2 prior lines of therapy including bortezomib and lenalidomide.

               -  Be refractory or intolerant to lenalidomide.

               -  Be refractory to the last line of therapy.

               -  Refractoriness to any therapy is defined as either failure to achieve minimal
                  response with it, or development of progressive disease (PD) while on therapy or
                  within 60 days after finishing it.

               -  At least two cycles of treatment must have been received, unless PD is documented
                  earlier.

          -  Only for the Phase II, patients must have measurable disease, defined as any of the
             following:

               -  Serum monoclonal protein value ≥ 500 mg/dl.

               -  Urine light chain excretion ≥ 200 mg/24 hours.

               -  Abnormal serum free light chains (FLCs) ratio plus involved FLC level ≥ 10 mg/dl.

        Exclusion Criteria:

          -  Prior therapy with Filanesib or pomalidomide.

          -  Non-adequate hematological or biochemical parameters as specified below:

          -  Hemoglobin &lt; 8.0 g/dl.

          -  Platelets count &lt; 75 x109/L without previous platelet transfusions in the last 7 days.
             If high bone marrow infiltration (&gt;50%) is present, ≥ 50 x109/L platelet count is
             required.

          -  Neutrophils (ANC) &lt;1.5 × 109/L without growth factor support (defined as no growth
             factor administration for at least 14 days prior to observation). If the bone marrow
             contains ≥ 50% plasma cells, a neutrophil count ≥1.0 × 109/L is allowed.

          -  Aspartate transaminase (AST): &gt; 2.5 x the upper limit range.

          -  Alanine transaminase (ALT): &gt; 2.5 x the upper limit range.

          -  Total bilirubin: &gt; 2 x the upper limit range.

          -  Creatinine clearance: &lt; 45 mL/min (measured or calculated with the Cockcroft and Gault
             formula).

          -  Absence of recovery from any significant non-hematological toxicity derived from
             previous treatments. The presence of alopecia and NCI-CTC grade &lt; 2 symptomatic
             peripheral neuropathy is allowed.

          -  Concomitant anti-myeloma therapy, including corticosteroids at a dose greater than 10
             mg/d prednisone or equivalent, within 14 days prior to Day 1 of Cycle 1.

          -  Pregnant or lactating women; men and women of reproductive potential who are not using
             highly effective contraceptive methods.

          -  Previous history of any other malignancy in the last five years (except basal cell
             carcinoma, skin epithelioma or carcinoma in situ of any site).

          -  Prior allogeneic bone marrow transplantation in the six prior months or active GVHD in
             the past month prior to cycle 1, day 1.

          -  Other relevant diseases or adverse clinical conditions:

          -  Congestive heart failure or unstable angina pectoris, myocardial infarction within 12
             months before inclusion in the study.

          -  Uncontrolled arterial hypertension or unstable cardiac arrhythmias (i.e. requiring a
             change in medication within the last 3 months or a hospital admission within the past
             6 months).

          -  History of significant neurological or psychiatric disorders.

          -  Active infection.

          -  Significant non-neoplastic liver disease (e.g., cirrhosis, active chronic hepatitis).

          -  Uncontrolled endocrine diseases (e.g. diabetes mellitus, hypothyroidism or
             hyperthyroidism) (i.e. requiring relevant changes in medication within the last month,
             or hospital admission within the last 3 months).

          -  Patient is known to be human immunodeficiency virus (HIV) positive, Hepatitis B
             surface antigen-positive or active hepatitis C infection.

          -  Limitation of the patient's ability to comply with the treatment or follow-up
             protocol.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ocio Enrique, DR</last_name>
    <role>Principal Investigator</role>
    <affiliation>PETHEMA Foundation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Instoitut Català d'Oncologia</name>
      <address>
        <city>Badalona</city>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Universitario</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Doce de Octubre</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Morales Messeguer</name>
      <address>
        <city>Murcia</city>
        <zip>30008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clínica Universitaria de Navarra</name>
      <address>
        <city>Pamplona</city>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hoapital Clinico Universitario Salamanca</name>
      <address>
        <city>Salamanca</city>
        <zip>37007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General de Segovia</name>
      <address>
        <city>Segovia</city>
        <zip>40002</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen del Rocío</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Dr Peset</name>
      <address>
        <city>Valencia</city>
        <zip>46017</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Lozano Blesa</name>
      <address>
        <city>Zaragoza</city>
        <zip>50009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <reference>
    <citation>Kyle RA, Rajkumar SV. Multiple myeloma. N Engl J Med. 2004 Oct 28;351(18):1860-73. Review. Erratum in: N Engl J Med. 2005 Mar 17;352(11):1163.</citation>
    <PMID>15509819</PMID>
  </reference>
  <reference>
    <citation>Kyle RA, Rajkumar SV. Multiple myeloma. Blood. 2008 Mar 15;111(6):2962-72. doi: 10.1182/blood-2007-10-078022. Review.</citation>
    <PMID>18332230</PMID>
  </reference>
  <reference>
    <citation>Kumar SK, Lee JH, Lahuerta JJ, Morgan G, Richardson PG, Crowley J, Haessler J, Feather J, Hoering A, Moreau P, LeLeu X, Hulin C, Klein SK, Sonneveld P, Siegel D, Bladé J, Goldschmidt H, Jagannath S, Miguel JS, Orlowski R, Palumbo A, Sezer O, Rajkumar SV, Durie BG; International Myeloma Working Group. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study. Leukemia. 2012 Jan;26(1):149-57. doi: 10.1038/leu.2011.196. Epub 2011 Jul 29. Erratum in: Leukemia. 2012 May;26(5):1153. Nari, Hareth [corrected to Nahi, Hareth].</citation>
    <PMID>21799510</PMID>
  </reference>
  <reference>
    <citation>Ocio EM, Richardson PG, Rajkumar SV, Palumbo A, Mateos MV, Orlowski R, Kumar S, Usmani S, Roodman D, Niesvizky R, Einsele H, Anderson KC, Dimopoulos MA, Avet-Loiseau H, Mellqvist UH, Turesson I, Merlini G, Schots R, McCarthy P, Bergsagel L, Chim CS, Lahuerta JJ, Shah J, Reiman A, Mikhael J, Zweegman S, Lonial S, Comenzo R, Chng WJ, Moreau P, Sonneveld P, Ludwig H, Durie BG, Miguel JF. New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG). Leukemia. 2014 Mar;28(3):525-42. doi: 10.1038/leu.2013.350. Epub 2013 Nov 20. Review.</citation>
    <PMID>24253022</PMID>
  </reference>
  <reference>
    <citation>Mateos MV, Ocio EM, San Miguel JF. Novel generation of agents with proven clinical activity in multiple myeloma. Semin Oncol. 2013 Oct;40(5):618-33. doi: 10.1053/j.seminoncol.2013.07.005. Review.</citation>
    <PMID>24135407</PMID>
  </reference>
  <reference>
    <citation>Miguel JS, Weisel K, Moreau P, Lacy M, Song K, Delforge M, Karlin L, Goldschmidt H, Banos A, Oriol A, Alegre A, Chen C, Cavo M, Garderet L, Ivanova V, Martinez-Lopez J, Belch A, Palumbo A, Schey S, Sonneveld P, Yu X, Sternas L, Jacques C, Zaki M, Dimopoulos M. Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial. Lancet Oncol. 2013 Oct;14(11):1055-1066. doi: 10.1016/S1470-2045(13)70380-2. Epub 2013 Sep 3.</citation>
    <PMID>24007748</PMID>
  </reference>
  <reference>
    <citation>Ocio EM, Mitsiades CS, Orlowski RZ, Anderson KC. Future agents and treatment directions in multiple myeloma. Expert Rev Hematol. 2014 Feb;7(1):127-41. doi: 10.1586/17474086.2014.858595. Epub 2013 Dec 18. Review.</citation>
    <PMID>24350987</PMID>
  </reference>
  <reference>
    <citation>Blangy A, Lane HA, d'Hérin P, Harper M, Kress M, Nigg EA. Phosphorylation by p34cdc2 regulates spindle association of human Eg5, a kinesin-related motor essential for bipolar spindle formation in vivo. Cell. 1995 Dec 29;83(7):1159-69.</citation>
    <PMID>8548803</PMID>
  </reference>
  <reference>
    <citation>Stern BM, Murray AW. Lack of tension at kinetochores activates the spindle checkpoint in budding yeast. Curr Biol. 2001 Sep 18;11(18):1462-7.</citation>
    <PMID>11566107</PMID>
  </reference>
  <reference>
    <citation>Tunquist BJ, Woessner RD, Walker DH. Mcl-1 stability determines mitotic cell fate of human multiple myeloma tumor cells treated with the kinesin spindle protein inhibitor ARRY-520. Mol Cancer Ther. 2010 Jul;9(7):2046-56. doi: 10.1158/1535-7163.MCT-10-0033. Epub 2010 Jun 22.</citation>
    <PMID>20571074</PMID>
  </reference>
  <reference>
    <citation>Boiani M, Daniel C, Liu X, Hogarty MD, Marnett LJ. The stress protein BAG3 stabilizes Mcl-1 protein and promotes survival of cancer cells and resistance to antagonist ABT-737. J Biol Chem. 2013 Mar 8;288(10):6980-90. doi: 10.1074/jbc.M112.414177. Epub 2013 Jan 22.</citation>
    <PMID>23341456</PMID>
  </reference>
  <reference>
    <citation>Lonial S, Shah JJ, Zonder J, Bensinger WI, Cohen AD, Kaufman JL, et al. Prolonged Survival and Improved Response Rates With ARRY-520 In Relapsed/Refractory Multiple Myeloma (RRMM) Patients With Low α-1 Acid Glycoprotein (AAG) Levels: Results From a Phase 2 Study. Blood. 2013;122(21):285-</citation>
  </reference>
  <reference>
    <citation>Shah JJ, Thomas S, Weber DM, Wang M, Orlowski R. Phase 1 Study Of The Novel Kinesin Spindle Protein Inhibitor Arry-520 + Carfilzomib(Car) In Patients With Relapsed And/Or Refractory Multiple Myeloma (RRMM). Haematologica. 2013;98(S1):Abstract-S579</citation>
  </reference>
  <reference>
    <citation>Humphries MJ, Anderson D, Williams L, Rieger R, Tunquist B, Walker D. ARRY-520 Combined With Pomalidomide Displays Enhanced Anti-Tumor Activity In Preclinical Models Of Multiple Myeloma. Blood. 2013;122(21):3167</citation>
  </reference>
  <results_reference>
    <citation>Petrelli NJ, Winer EP, Brahmer J, Dubey S, Smith S, Thomas C, Vahdat LT, Obel J, Vogelzang N, Markman M, Sweetenham JW, Pfister D, Kris MG, Schuchter LM, Sawaya R, Raghavan D, Ganz PA, Kramer B. Clinical Cancer Advances 2009: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology. J Clin Oncol. 2009 Dec 10;27(35):6052-69. doi: 10.1200/JCO.2009.26.6171. Epub 2009 Nov 9. Review.</citation>
    <PMID>19901123</PMID>
  </results_reference>
  <results_reference>
    <citation>Kumar SK, Rajkumar SV, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Zeldenrust SR, Dingli D, Russell SJ, Lust JA, Greipp PR, Kyle RA, Gertz MA. Improved survival in multiple myeloma and the impact of novel therapies. Blood. 2008 Mar 1;111(5):2516-20. Epub 2007 Nov 1.</citation>
    <PMID>17975015</PMID>
  </results_reference>
  <results_reference>
    <citation>Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T, Harousseau JL, Ben-Yehuda D, Lonial S, Goldschmidt H, Reece D, San-Miguel JF, Bladé J, Boccadoro M, Cavenagh J, Dalton WS, Boral AL, Esseltine DL, Porter JB, Schenkein D, Anderson KC; Assessment of Proteasome Inhibition for Extending Remissions (APEX) Investigators. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med. 2005 Jun 16;352(24):2487-98.</citation>
    <PMID>15958804</PMID>
  </results_reference>
  <results_reference>
    <citation>Singhal S, Mehta J, Desikan R, Ayers D, Roberson P, Eddlemon P, Munshi N, Anaissie E, Wilson C, Dhodapkar M, Zeddis J, Barlogie B. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med. 1999 Nov 18;341(21):1565-71. Erratum in: N Engl J Med 2000 Feb 3;342(5):364.</citation>
    <PMID>10564685</PMID>
  </results_reference>
  <results_reference>
    <citation>Dimopoulos M, Spencer A, Attal M, Prince HM, Harousseau JL, Dmoszynska A, San Miguel J, Hellmann A, Facon T, Foà R, Corso A, Masliak Z, Olesnyckyj M, Yu Z, Patin J, Zeldis JB, Knight RD; Multiple Myeloma (010) Study Investigators. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med. 2007 Nov 22;357(21):2123-32. Erratum in: N Engl J Med. 2009 Jul 30;361(5):544.</citation>
    <PMID>18032762</PMID>
  </results_reference>
  <results_reference>
    <citation>Weber DM, Chen C, Niesvizky R, Wang M, Belch A, Stadtmauer EA, Siegel D, Borrello I, Rajkumar SV, Chanan-Khan AA, Lonial S, Yu Z, Patin J, Olesnyckyj M, Zeldis JB, Knight RD; Multiple Myeloma (009) Study Investigators. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med. 2007 Nov 22;357(21):2133-42.</citation>
    <PMID>18032763</PMID>
  </results_reference>
  <results_reference>
    <citation>Milross CG, Mason KA, Hunter NR, Chung WK, Peters LJ, Milas L. Relationship of mitotic arrest and apoptosis to antitumor effect of paclitaxel. J Natl Cancer Inst. 1996 Sep 18;88(18):1308-14.</citation>
    <PMID>8797771</PMID>
  </results_reference>
  <results_reference>
    <citation>Oltersdorf T, Elmore SW, Shoemaker AR, Armstrong RC, Augeri DJ, Belli BA, Bruncko M, Deckwerth TL, Dinges J, Hajduk PJ, Joseph MK, Kitada S, Korsmeyer SJ, Kunzer AR, Letai A, Li C, Mitten MJ, Nettesheim DG, Ng S, Nimmer PM, O'Connor JM, Oleksijew A, Petros AM, Reed JC, Shen W, Tahir SK, Thompson CB, Tomaselli KJ, Wang B, Wendt MD, Zhang H, Fesik SW, Rosenberg SH. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature. 2005 Jun 2;435(7042):677-81. Epub 2005 May 15.</citation>
    <PMID>15902208</PMID>
  </results_reference>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 1, 2015</study_first_submitted>
  <study_first_submitted_qc>March 9, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 10, 2015</study_first_posted>
  <last_update_submitted>May 22, 2018</last_update_submitted>
  <last_update_submitted_qc>May 22, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Multiple Myeloma</keyword>
  <keyword>Pethema</keyword>
  <keyword>Filanesib</keyword>
  <keyword>Pomalidomide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Pomalidomide</mesh_term>
    <mesh_term>Thalidomide</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

